Tag: Measure 109

Proposed Federal Amendment Would Unleash Psychedelic Research

I’m old enough to remember some heartbreaking federal congressional votes on medical cannabis. The federal amendment prohibiting the federal government from prosecuting state-legal medical cannabis patients and providers took passed on the seventh attempt. While it’s easy to take for granted how far we’ve come and be impatient for the United States Senate to join their counterparts in the House in passing a bill to end federal prohibition, advocates may want to temper expectations a bit and practice patience, for their own sanity and to avoid burnout, if history is any guide. Double your mindfulness and meditation if you are expecting Congress to pass sensible psychedelics legislation, but thanks to Representative Alexandria Ocasio-Cortez, we’ve taken the first couple of steps on the journey. Marijuana Moment reported on AOC’s second filing of an amendment to allow federal funding of psychedelic research:

“Ocasio-Cortez’s proposal is especially notable given its focus on psychedelics—an issue that’s rarely been breached in Congress. Her measure would strike a longstanding rider, first enacted in 1996, that prohibits the use of federal funds for ‘any activity that promotes the legalization of any drug or other substance in Schedule I.’

“A description of the amendment clarifies that the intent is to allow ‘United States researchers to study and examine the potential impacts of several schedule I drugs, such as MDMA, psilocybin, and or ibogaine, that have been shown to be effective in treating critical diseases.’

“In 2019, a large majority of Democratic House members joined all but seven Republicans in a vote against an earlier version of the congresswoman’s amendment. But given the surge in state and local psychedelics reform efforts in the years since, it stands to reason that this Congress may take the issue more seriously.”

While it’s always disappointing to lose important votes, it’s all a part of the process towards educating legislators while changing the political calculations of elected officials by demonstrating public support, and most importantly, winning elections. Psychedelic research isn’t going to benefit the current special interests that fill up campaign coffers, so it’s going to take some time. Oregon voters passing Measure 109 to legalize therapeutic psilocybin therapy and Measure 110 to decriminalize personal possession of all drugs was a start, just as California kicked off a winning stretch for cannabis by passing the Prop 215 medical measure all the way back in 1996. As we win elections state by state, we can expect for those political victories and scientific advancements to resonate more forcefully throughout the halls of Congress.

No matter your kind of trip, to the mountains, river, high desert, or staying at home, Kind Leaf, Pendleton’s premier craft cannabis boutique, should be your first stop. We are proud of Oregonians leading the way and are looking forward to what the future holds for all of us as we all remember to be kind to one another.

Can Psychedelics Help Patients Combat Obesity?

Despite the “munchies” that cannabis can seem to cause, the evidence has shown that the cannabis community tends to be less obese than the general population. For those of us that continue to battle with maintaining a healthy wait, maybe psychedelics could potentially unlock the answer. While there is currently a lack of human data on the issue, there has been promising results from research on lab rats, and we can expect more studies to be conducted on a whole host of health issues, as psychedelic medicine follows a similar path as medicinal cannabis. Clive Ward Able, MD, a trained physician and pharmacist, discussed his research into the use of psychedelic compounds to treat obesity and optimize human health with Pharmacy Times:

“’The idea is that this has to come from the patient. If the patient wants help for it, this will be able to help them get to a place where they really want to be,’ Ward Able said. ‘But I’m not talking about every single obese patient, because there are a lot of obese patients who are happy the way they are, and they don’t necessarily want to lose weight. But there’s a large component of those, such as in depressed patients, who have certain triggers that get them to overeat or not to exercise, etc.’

Ward Able noted that the target of obesity treatment is not necessarily to bring every patient under a body mass index of 25. Instead, this treatment can hopefully allow patients to get to a healthier weight and maintain it, with an added sense of wellbeing that they may desire after losing weight.

“’This is where I think psychedelics can add to what is being done now,’ Ward Able said. ‘Psychotherapies are being used for the treatment of obesity or weight management, but people tend to fall back into their old behaviors again, although they do work. What I’m calling drug enhanced psychotherapy or psilocybin-assisted psychotherapy adds another facet to that psychotherapy, which should be able to instill much longer lasting positive behaviors, such as an improved diet, whether that’s quantity or quality, or within expenditure of energy, such as increasing your amount of exercise.’”

As Dr. Ward states, psychedelics could be a key to maintaining a healthy weight by helping patients deal with underlying issues such as depression, that are causing unhealthy life choices. With obesity impacting over 42% of American adults and over 8% experiencing depression, millions of people battling mental health issues and the corresponding weight gain, could benefit from psychedelics. With therapeutic psilocybin treatments less than two years away in Oregon thanks to the passage of Measure 109, we will soon have an abundance of evidence about the benefits of “magic mushrooms” and as the Measure 110 drug decriminalization law helps end the stigma around the use of all psychedelics, we will only see more research into how many of these psychoactive substances can help a variety of conditions. Stay tuned, as it is an exciting time for psychedelic medicine.

Whether you are looking to gain weight, lose weight, or maintain, Kind Leaf has your back and all of your cannabis needs. Check out the best selection in the Great Northwest and you can even order online via Leafly to save time. As always, there are discounts available for military veterans, senior citizens, and OMMP patients. Until supplies last, clones are 75% off, making them just $7.50!!!

California Psychedelics Legalization Bill Moves Forward with Changes

The legislative process is often compared to sausage making, something extremely messy and not something pleasant to watch. As a veteran of several lobbying efforts, I tend to agree, but it’s a necessary endeavor that, when done right, can improve and save lives. California Senate Bill 519, championed by Senator Scott Wiener, is a proposal followed very closely by Drug War reform advocates, so even though things can get ugly, we can’t take our eye off of another potential big swing against prohibition. After passing the full Senate, SB 519 has now cleared a major hurdle in the state’s General Assembly by passing the Committee on Health, but a few amendments have complicated matters on both legislative and activist fronts. Despite the complications, we can still count this progress as a win in our fight against prohibition.

Marijuana Moment covered important details on the landmark bill that would remove criminal penalties for adults 21 and over for the possession of many psychedelics such as psilocybin, DMT, LSD and MDMA:

“Now, as a result of changes approved by the latest panel, the bill includes language laying out the limits for what is an allowable personal possession amount for each substance. That’s led Decriminalize Nature (DN), a group that’s worked to enact psychedelics reform across the country, to call for the tabling of the legislation.


“As passed in committee on Tuesday, these are the prescribed limits for personal possession that would be legalized:

-2 grams of DMT

-15 grams of ibogaine

-0.01 grams of LSD

-4 grams of mescaline

-2 grams of the controlled substance psilocybin or 4 ounces of a plant or fungi containing the controlled substance psilocybin.

-2 grams of the controlled substance psilocyn or 4 ounces of a plant or fungi containing the controlled substance of psilocyn

-4 grams of MDMA.”

David Bronner, CEO of Dr. Bronner’s Magic Hemp Soaps, who is a major funder of drug reform efforts, including of Oregon Measures 91, 109, and 110, is urging advocates to not let the perfect be the enemy of the good and continue supporting SB 519. While I tend to defer to activists on the ground in the state at hand, I do wholeheartedly agree with Bronner. Holding up important legislation on the hope that a bill without any possession limits can pass is a risky proposition that will lead to more harmful arrests and convictions in the meantime. Such bills are also easy to demonize by opponents. For example, Oregon Measure 80 would have legalized an unlimited amount of cannabis in 2012, but voters rejected that initiative, but passed M91, which included limits, just two years later.

A sincere thanks to Senator Wiener and all of the activists doing the heavy lifting in the Golden State for Senate Bill 519. No matter what happens this legislative session, the progress thus far is really impressive and inspirational. This work will resonate forward and reverberate across state lines.

Kind Leaf continues to be proud of hardworking advocates looking to save and improve lives by moving away from the Drug War and towards a health-based approach.

Study Shows Psilocybin Regrowing Brain Tissue Damaged by Depression

Depression impacts millions of Americans, with over 17% of adults suffering a major depressive issue. Depression can cause feelings of sadness and despair and potentially a loss of interest in things that once caused happiness. The mental and physical issues caused by this mental health condition can understandably hinder one’s work productivity and social relationships. The good news is that depression is treatable and advancements in psychedelics are potentially opening up new treatment avenues. A recent study by Yale researchers shows that psilocybin, the psychoactive ingredient in “magic mushrooms” may actually regrow brain tissue damaged by depression, as covered by Interesting Engineering:

“A psychedelic drug called psilocybin, which shows up naturally in some mushrooms, has shown signs of increasing durable connections between neurons in mouse brains, according to a new study published in the journal Neuron.

“In other words, the damage depression does to your brain might be reversible with psychedelic mushrooms, and scientists think the trip itself could play a vital role.

“‘We not only saw a 10% increase in the number of neuronal connections, but also they were on average about 10% larger, so the connections were stronger as well,’ said the study’s lead author Alex Kwan, who is also an associate professor of both psychiatry and neuroscience at Yale, in an embargoed release shared with IE. Earlier laboratory experiments hinted that psilocybin, in addition to the anesthetic ketamine, can reduce the effects of depression. But this latest research showed these compounds also increase the density of dendritic spines, creating small protrusions on nerve cells capable of enhancing the way information transmits from one neuron to the next. Depression and chronic stress are known factors in the reduction of these crucial neuronal connections.”

While legalized psilocybin therapy is likely years away for most, Oregon is leading the way following the passage of Measure 109. In less than two years, state-licensed and regulated psilocybin therapy will be available to help treat a whole host of mental health ailments, including depression. As more studies demonstrate the benefit of magic mushrooms and other psychedelics, Oregon needs to continue to be on the forefront of this growing medical revolution, and other states will certainly follow. Just as federal cannabis prohibition is about to crumble, we have an opportunity to create a similar movement for psychedelics, improving lives along the way.

No matter your trip, whether it is an adventure into the woods, kayaking on a river, just chilling in your living room, or whatever your heart desires, Kind Leaf is there for you. Come into our shop and check out the best selection of cannabis in the Great Northwest or conveniently shop online via Leafly. Always be sure to check out our latest deals and remember that we provide discounts to military veterans, senior citizens, and OMMP patients.

Celebrate Oregon’s Cannabis Legalization Anniversary with Kind Leaf

It’s been 6 years since the great state of Oregon officially legalized cannabis for adults at least 21 years old and it’s been a wild ride with ups and downs and twist and turns, but Oregonians can be proud of our pioneering spirit creating more freedom, jobs, and revenue. The Beaver State has a long history of helping lead the nation away from Reefer Madness prohibition, starting with becoming the first state to decriminalize personal possession all the way back in 1973, being one of the early states to adopt medical and adult use laws, and now leading the charge against the failed Drug War with the passage of the landmark Measure 109 psilocybin therapy and Measure 110 drug decriminalization laws in 2020.

Each advancement helps set the stage for the next positive step and needless to say, Measure 110 wouldn’t have passed without the Measure 91 legalization law leading the way in 2014. While a few counties defacto legalized before July 1, 2015, with lead prosecutors announcing that they would follow the will of the voters early, the first day of July marks when the entire state officially ended prohibition within its borders.

Come celebrate Oregon’s cannabis legalization anniversary and stock up for your July 4th celebration at Kind Leaf, Pendleton’s premier craft cannabis boutique. At Kind Leaf, you get the best selection and you are supporting local small business that gives back to the community.

This week’s specials at Kind Leaf, until July 5th or supplies last (and please remember that there are always discounts for military veterans, OMMP patients, and senior citizens):


15% OFF – Paradise Circus and MAC

30% OFF – Tokyo Snow and Strawberry Cream

40% OFF – Charvak and DoggFace Prepacked Flower 1/8th


15% OFF – Gron Pips and Estaweeda Granola

30% OFF – Mule Kicker Gummy – Hella Melon, LOL Doob Cube – Mango and Happy Cabbage Hemp Tinctures


15% OFF – Quantum Alchemy Extracts

30% OFF – Bobsled Extracts, Willamette Valley Alchemy .5g Vapes and Shatters

40% OFF – Highland Provision .5g Live Rosin Vape – Lemon Royale


15% OFF – Epic Family Farm Packs Prerolls

30% OFF – Loyal Prerolls

While it is amazing to be able to legally purchase cannabis and other products, most importantly we have improved lives by ending thousands of harmful arrests and expunging criminal convictions. Just over a decade ago, nearly 15,000 people were being arrested and cited for cannabis, and now it’s less than 1,000. In 2010, there almost 30,000 people were arrested/cited for drug offenses, and now it’s less than 10,000 while that number will plummet even more thanks to the passage of Measure 110. Racial disparities in drug arrests have also decreased and our state has reallocated tens of millions of dollars away from investing in the prison-industrial complex to investing in our people, funding much-needed and life-saving treatment, harm reduction, and recovery programs.

There’s more work to be done to fully dismantle the Drug War and bring more equity and justice to the cannabis community, but we can take a moment to enjoy the gains that we’ve made. And as Oregonians celebrate the 6th year of legal cannabis, we are joined by Connecticut and Virginia who just became legal as well. Now, more than 40% of our nation live in states with legal cannabis. A sincere thanks to all advocates that are working to legalize freedom. Step by step, state by state, until we are all equal and free.

Oregon Measure 109 Inspires Florida Psychedelic Treatment Advocates

“When Measure 109 passed in Oregon is when we really got excited and said we think we should get something filed here in Florida.”

Drug War opponents make an interesting team. We could be on the same team even though we’ve never communicated, let alone met, and our immediate and future political goals differ in various ways. Those fighting the War on Drugs are ultimately seeking to put an end to harmful arrests and convictions that have ruined too many lives and wasted too many resources already, but we must work within the reality of our state. What is capable of passing with voters or legislators in Oregon is much different than what may pass in Texas or Florida, but while voters in other states may not be ready to decriminalize personal drug possession like Measure 110 accomplished last November or establish a psilocybin therapy model as allowed under Measure 109, the victories create momentum for other advocates to take positive steps forward in their states.

When reading about legislation introduced in Florida, it was heartening to hear Mr. Psychedelics Law President Dustin Robinson, a Fort Lauderdale-based attorney who helped draft a statewide psilocybin bill, give credit to Oregon Measure 109 as inspiration. ABC Channel 7 out of southwestern Florida recently reported on the burgeoning psychedelic treatment activist community in the Sunshine State, from those working to change the law to those currently operating ketamine therapy clinics:

“It isn’t just a psychedelic revolution it’s a consciousness revolution,” Robinson said. “We’re in a mental health crisis and we have the solution right in front of us. All we have to do is create the legal framework to allow it to come to light.”

Robinson said he expects psilocybin to get legalized in Florida over the next 4-6 years if not sooner. If magic mushrooms and MDMA clear more hurdles he said we could start seeing psychedelic centers opening up similar to the ones administering ketamine.

The psychedelics treatment movement takes me back to the years following the passage of our nation’s first medical cannabis initiatives. One of the most fascinating aspects of working in drug policy reform is learning something new nearly every single day. Every week there is new research being conducted or positive legislation introduced or a new victory to celebrate. Each step forward leads to another step forward, whether it is in your state or another state all the way across the nation, moving us forward towards a sane and compassionate drug policy that invests in people instead of prison. A sincere thanks to everyone that worked hard to pass Measure 109 and to Oregon voters for seeing through Drug War propaganda; your impact is reverberating far beyond the Beaver State’s borders.

California Psychedelics Decriminalization Bill Heads to the Senate

California started our nation’s state-by-state medical cannabis political revolution by first passing Proposition 215 back in 1996, with Oregon and Washington following suit with their own medicinal initiatives in ’98. With Oregon Measure 109 leading the way on therapeutic psilocybin and Measure 110 the first successful drug decriminalization in the U.S. in 2020, it appears that the Beaver State may be returning the favor for its southern neighbor as California has just moved one step closer to allowing the personal possession, use, and sharing of psychedelics. Senate Bill 519, sponsored by Senator Scott Wiener, has passed out of the Senate Appropriations Committee, paving the way for a vote before the Senate. If successful there, the psychedelics bill would go before the California Assembly ahead of a potential trip to the governor’s desk. Marijuana Moment reported:

If enacted into law, the bill would remove criminal penalties for possessing or sharing numerous psychedelics—including psilocybin mushrooms, DMT, ibogaine, LSD and MDMA—for adults 21 and older.


Under the bill, state Department of Public Health would be required to establish a working group “to study and make recommendations regarding possible regulatory systems that California could adopt to promote safe and equitable access to certain substances in permitted legal contexts.” Those recommendations would be due by January 1, 2024.

For psilocybin specifically, the legislation would repeal provisions in California statute that prohibit the cultivation or transportation of “any spores or mycelium capable of producing mushrooms or other material” that contain the psychoactive ingredient.

Hopefully, California legislators will make informed votes based upon science and common sense and won’t be unduly swayed by Drug War propaganda. The War on Drugs simply hasn’t worked and there’s no reason to ruin lives over the personal possession of psychedelics. With the research coming out of institutions like Johns Hopkins and voters and policymakers understanding that it’s time to end the grip that the prison-industrial complex has had over drug policy, there’s never been a better time to implement much-needed reforms. It’s time to invest in people instead of more prisons. Whether SB 519 passes this year or not, it’s a great step in the right direction to see this much progress being made on the heels of Oregon Measures 109 and 110. It’s easy to see a future where states are passing drug decriminalization laws in a similar manner as we’ve seen with cannabis. A sincere thanks to everyone fighting the good political fight.

Scientific American: Psychedelic with Therapy Significantly Improves PTSD Symptoms

Posttraumatic stress disorder (PTSD) impacts about 3.5% of all adults in the United States every year, while nearly 10% will get diagnosed during their lifetime. People across all demographics may develop PTSD after experiencing or witnessing a traumatic event and symptoms can vary over time. According to the Mayo Clinic, most people who go through a terrifyingly traumatic event have a temporary difficulty adjusting immediately. Effective treatment can be crucial to effectively coping and improving function. May is Mental Health Awareness Month and it’s extremely important to educate folks on the prevalence of mental health issues and to put an end to any remaining stigma that may prevent people from seeking treatment. Scientists are starting to discover psychedelics’ role in treating PTSD and other mental health conditions, and as Scientific American reported, MDMA combined with therapy appears to improve symptoms:

“A long-awaited study is making worldwide headlines for finding that the outlawed psychoactive drug MDMA is startlingly effective in treating post-traumatic stress disorder (PTSD). But researchers and study participants say the substance itself, while extremely powerful, catalyzes healing rather than working on its own: MDMA treatment also requires dozens of hours of therapy—before, during and after the drug experience—with professionals whose special training is expensive and intense.

“Researchers hope the new study, published this week in Nature Medicine, will help this treatment gain regulators’ approval for clinical use within a couple of years. Many therapists and patients are thrilled: About two thirds of PTSD sufferers do not respond to other treatments. And MDMA had shown tremendous promise in earlier, smaller studies.”

“PTSD is a difficult nut to crack—one main reason being that traumas become stuck,” explains Jennifer Mitchell, a neuroscientist at the University of California, San Francisco, and lead author of the study. “But with MDMA, things that had really crystallized become more flexible, and this gives you the chance to shake the tree and let all the nuts fall out.”

Just as countless lives have benefitted from the medicinal use of cannabis, it appears that psychedelics may be on a similar path towards more scientific discoveries that can unlock mental health benefits. Drug policy reforms and research are going hand-in-hand to educate the public, reduce stigma, and open up new avenues for important studies. The passage of Measure 109 and 110 in Oregon have set the stage for potential legislation in California, and other states will utilize the latest evidence to make informed decisions around important drug policy decisions. As more research is conducted, the medicinal use of psychedelics will become more mainstream across our nation and the globe.

Friendly reminder: Kind Leaf supports all OMMP patients, senior citizens, and military veterans with discounts every day.

Johns Hopkins Endows First Professorship on the Planet with Psychedelics in the Title

It’s evident that we are in the midsts of a psychedelic medicine revolution, relatively similar to the medicinal cannabis movement during the 1990s. As with any movement, there are giants that paved the way by challenging social and cultural norms while combating Drug War propaganda and policies, with each positive step creating more space for others to follow. Whether in science or politics, pioneers of movements, many of whom remain hidden from the limelight and accolades from most, make change possible. Sometimes major breakthroughs seem decades away, if even possible, and then suddenly, anything and everything seems on the horizon. Will drug policy reformers look back at Oregon Measures 109 and 110 in the same way that we look back at California Proposition 215 legalizing medical cannabis back in 1996? Potentially, but only time will tell.

Before Oregon voters allowed medicinal psilocybin treatment and decriminalized personal drug possession, there were several successful local measures, and decades of important research that made change possible in 2020. I imagine that many, certainly myself, will look back at Johns Hopkins University endowing the Susan Hill Ward Professor in Psychedelics and Consciousness at Johns Hopkins University to Matthew Johnson as one of the foundational milestones of the psychedelics movement, if not in the greater battle to implement more sane and sensible drug policies, based upon science instead of misinformation and hyperbole. For too long, the prison-industrial complex and other special interests have perpetuated harmful propaganda designed to dehumanize and delegitmize people, with dreadful consequences, including a mass incarceration epidemic that remains an international embarrassment.

Last November, Johns Hopkins released the press release, “Psychedelic Treatment with Psilocybin Relieves Major Depression, Study Shows”:

“In a small study of adults with major depression, Johns Hopkins Medicine researchers report that two doses of the psychedelic substance psilocybin, given with supportive psychotherapy, produced rapid and large reductions in depressive symptoms, with most participants showing improvement and half of study participants achieving remission through the four-week follow-up.

“A compound found in so-called magic mushrooms, psilocybin produces visual and auditory hallucinations and profound changes in consciousness over a few hours after ingestion. In 2016, Johns Hopkins Medicine researchers first reported that treatment with psilocybin under psychologically supported conditions significantly relieved existential anxiety and depression in people with a life-threatening cancer diagnosis.

“Now, the findings from the new study, published Nov. 4 in JAMA Psychiatry, suggest that psilocybin may be effective in the much wider population of patients who suffer from major depression than previously appreciated.”

Professor Johnson tweeted that, “To my knowledge this is the 1st endowed professorship on the planet with psychedelics in the title.” I’m willing to bet that he certainly won’t be the last. Johns Hopkins University is one of the top academic institutions in the world, receiving the most U.S. federal research funds, affiliated with over 35 Nobel Laureates. We will only be seeing more important research originate with Johns Hopkins’ Center for Psychedelic and Consciousness Research and other universities will certainly follow suit.

Psychedelic Scientists Decry Drug War Obstacles at Psilocybin Research Event

The War on Drugs causes so much unnecessary heartache and pain, from unnecessary arrests to exorbitant taxes that prevent hardworking mom-and-pop entrepreneurs from achieving their American Dream. The unnecessary obstacles stifling medical research is one of the many ills of the Drug War, preventing people from saving and improving their lives with safe medical options. The cannabis community knows all too well the ridiculous barriers put in place whenever researchers attempt to study federal Schedule I substances. Now, with psychedelic research following in the footsteps of cannabis, scientists are facing similar nonsensical hurdles that needlessly delay the ability to find safe medicines just waiting to be unlocked. As Marijuana Moment reported, prominent scientists decried these outdated Drug War obstacles at the inaugural Psilocybin Research Speaker Series event hosted by the National Cancer Institute (NCI), under the National Institutes of Health (NIH), on April 22nd:

A federal health agency kicked off a speaker series on Thursday that’s dedicated to recapping science on the therapeutic potential of psilocybin mushrooms. And the experts who spoke at the first event said in response to Marijuana Moment’s questions that federal drug laws are out of step with voters and undermine the research objectives of the scientific community.


Asked by Marijuana Moment about whether the scheduling status of psilocybin under federal law inhibits research into the compound’s risk and benefits, Dr. Roland Griffiths of Johns Hopkins University said that the “Schedule I status is anathema to research because it makes research much more difficult—and that’s both clinical research and even preclinical research.”

“Even a preclinical neurological researcher, if they want to work with a Schedule I compound, they still have to jump through all the hurdles and create a [Drug Enforcement Administration] license and track their substance in a way that’s really quite discouraging of research,” he said. “I wish there were an easier workaround for Schedule I compounds and research generally, but as the laws are currently written, there isn’t a workaround.”

The National Cancer Institute has this to say about psilocybin and the current status of federal law and ongoing research:

“Psilocybin is the natural active compound found in more than 200 species of fungi, more commonly referred to as ‘magic mushrooms.’ Psilocybin is converted by the body to psilocin, which has hallucinogenic mind-altering properties. These naturally occurring mushrooms have been used anthropologically worldwide by indigenous cultures for centuries in the context of religious or spiritual healing ceremonies. Psilocybin is currently a Schedule I substance under the 1970 Controlled Substances Act (CSA). Schedule 1 classification defines chemicals or substances that, currently, have no accepted medical use and have a high potential for abuse. Advances in clinical trials, however, are researching psilocybin to treat cancer related depression, for example, and moreover for its potential medicinal application in treating a range of severe psychiatric disorders, such as: major depressive disorder, treatment resistant depression, post-traumatic stress disorder, opioid use disorder and other substance use disorders, as well as anorexia. To date, FDA granted two breakthrough therapy designations for psilocybin, one for treatment resistant depression in 2018, and a second for major depressive disorder in 2019.”

This is a fascinating time for drug policy activism, from legalizing cannabis to harnessing the healing properties of natural substances that have been wrongly criminalized. It’s great to seen Oregon, with the passage of Measure 109, helping lead the way.

If we can safely help people we should explore those avenues and let science be the guide, not decades of propaganda and misinformation. Too many of our citizens are suffering, whether they are veterans suffering from post-traumatic stress or everyday Americans combating PTSD or depression themselves. It’s great to see our nation take steps towards a sane drug policy and this federally-funded Psilocybin Research Speaker Series is a nice step in the right direction. There are more panels on May 27th and June 4th, 7th, and 10th covering a variety of topics including microdosing, group therapy, psychotherapy for cancer-related psychiatric distress, and more. You can see the full agenda and register here.

Even though 4/20 is behind us, there are still plenty of great deals at Kind Leaf to help uplift your mood. As always, senior citizens, military veterans, and OMMP patients qualify for discounts. Free online ordering through Leafly pickup for convenience or come on into Eastern Oregon’s premier craft cannabis boutique.